Baseline severe anaemia should not preclude use of zidovudine in antiretroviral-eligible patients in resource-limited settings

Journal of the International AIDS Society

Volumn 13, Issue 1, 2010, Pages

  Kiragga, Agnes N ^a   Castelnuovo, Barbara ^a   Nakanjako, Damalie ^a,b   Manabe, Yukari C ^a,c  

^a MAKERERE UNIVERSITY   (Uganda)

^b MAKERERE UNIVERSITY MEDICAL SCHOOL   (Uganda)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; STAVUDINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG USE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; TUBERCULOSIS; BLOOD; CLINICAL TRIAL; METABOLISM; RISK FACTOR; UGANDA;

ADULT; ANEMIA; ANTI-HIV AGENTS; FEMALE; HEMOGLOBINS; HIV INFECTIONS; HUMANS; MALE; RISK FACTORS; UGANDA; ZIDOVUDINE;

EID: 78049340819     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.1186/1758-2652-13-42     Document Type: Article

References (28)

1. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. PS Sullivan DL Hanson SY Chu JL Jones JW Ward, Blood 1998 91 1 301 308 9414298
2. Long-term survival in patients with advanced immunodeficiency. G Chene PJ Easterbrook E Juszczak LM Yu SJ Pocock BG Gazzard, AIDS 1997 11 2 209 16 10.1097/00002030-199702000-00012 9030369
3. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. A Mocroft S Madge AM Johnson A Lazzarin N Clumeck FD Goebel JP Viard J Gatell A Blaxhult JD Lundgren, J Acquir Immune Defic Syndr 1999 22 4 369 378 10634199
4. Anaemia in persons with HIV infection: prognostic marker and contributor to morbidity. G Moyle, AIDS Rev 2002 4 1 13 20 11998779
5. Anemia and survival in HIV infection. RD Moore JC Keruly RE Chaisson, J Acquir Immune Defic Syndr Hum Retrovirol 1998 19 1 29 33 9732065
6. Predictors of the acquired immunodeficiency syndrome developing in a cohort of seropositive homosexual men. BF Polk R Fox R Brookmeyer S Kanchanaraksa R Kaslow B Visscher C Rinaldo J Phair, N Engl J Med 1987 316 2 61 66 10.1056/NEJM198701083160201 3024007
7. Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infected and -uninfected women. RD Semba N Shah RS Klein KH Mayer P Schuman D Vlahov, Clin Infect Dis 2002 34 2 260 266 10.1086/338151 11740716
8. Impact of highly active antiretroviral therapy on anemia and relationship between anemia and survival in a large cohort of HIV-infected women: Women's Interagency HIV Study. K Berhane R Karim MH Cohen L Masri-Lavine M Young K Anastos M Augenbraun DH Watts AM Levine, J Acquir Immune Defic Syndr 2004 37 2 1245 1252 10.1097/01.qai.0000134759.01684.27 15385731
9. Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. F Ssali W Stohr P Munderi A Reid AS Walker DM Gibb P Mugyenyi C Kityo H Grosskurth J Hakim H Byakwaga E Katabira JH Darbyshire CF Gilks, Antivir Ther 2006 11 6 741 749 17310818
10. Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Cote d'Ivoire. R Moh C Danel S Sorho D Sauvageot A Anzian A Minga OB Gomis C Konga A Inwoley D Gabillard E Bissagnene R Salamon X Anglaret, Antivir Ther 2005 10 5 615 624 16152755
11. Anemia in HIV-infected patients receiving highly active antiretroviral therapy. RD Moore D Forney, J Acquir Immune Defic Syndr 2002 29 1 54 57 11782590
12. Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events. CJ Hoffmann KL Fielding S Charalambous MS Sulkowski C Innes CL Thio RE Chaisson GJ Churchyard AD Grant, AIDS 2008 22 1 67 74 10.1097/QAD.0b013e3282f2306e 18090393
13. Uganda Ministry of Heath, National Antiretroviral Treatment Guidelines for Adults, Adoloscents and Children 2008
14. When to start in resource-poor areas. [MOSY103]. F Venter, 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention Cape Town 2009
15. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. DD Richman MA Fischl MH Grieco MS Gottlieb PA Volberding OL Laskin JM Leedom JE Groopman D Mildvan MS Hirsch GG Jackson DT Durack S Nusinoff-Lehrman The AZT Collaborative Working Group, N Engl J Med 1987 317 4 192 197 10.1056/NEJM198707233170402 3299090
16. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. PA Volberding SW Lagakos MA Koch C Pettinelli MW Myers DK Booth HH Balfour Jr RC Reichman JA Bartlett MS Hirsch RL Murphy DW Hardy R Soeiro MA Fischl JG Bartlett TC Merigan NE Hyslop DD Richman FT Valentine L Corey the AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases, N Engl J Med 1990 322 14 941 949 10.1056/NEJM199004053221401 1969115
17. World Health Organization, Antiretroviral therapy for HIV infection in adults and adoloscents: Recommendations for a public health approach Geneva 2006
18. Ministry of Health, Republic of Uganda, Uganda National Antiretroviral Treatment and Care Guidelines for Adults, Adolescents and Children 2003
19. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases, Division of AIDS (DAIDS) Table for grading adult and pedicatric adverse experiences (Toxicity tables) 1994
20. R Little D Rubin, Statistical analysis with missing data New York: Wiley 1987
21. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JS Stringer I Zulu J Levy EM Stringer A Mwango BH Chi V Mtonga S Reid RA Cantrell M Bulterys MS Saag RG Marlink A Mwinga TV Ellerbrock M Sinkala, JAMA 2006 296 7 782 793 10.1001/jama.296.7.782 16905784
22. Adverse effects of highly active antiretroviral therapy in developing countries. R Subbaraman SK Chaguturu KH Mayer TP Flanigan N Kumarasamy, Clin Infect Dis 2007 45 8 1093 1101 10.1086/521150 17879931
23. Prior antiretroviral therapy experience protects against zidovudine-related anaemia. SE Huffam P Srasuebkul J Zhou A Calmy V Saphonn JM Kaldor R Ditangco, HIV Med 2007 8 7 465 471 10.1111/j.1468-1293.2007.00498.x 17760739
24. Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy. YC Manabe R Breen T Perti E Girardi TR Sterling, J Infect Dis 2009 199 3 437 444 10.1086/595985 19090776
25. Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapy. SM Curkendall JT Richardson MF Emons AE Fisher F Everhard, HIV Med 2007 8 8 483 490 10.1111/j.1468-1293.2007.00500.x 17944680
26. Haematological changes after switching from stavudine to zidovudine in HIV-infected children receiving highly active antiretroviral therapy. L Aurpibul T Puthanakit T Sirisanthana V Sirisanthana, HIV Med 2008 9 5 317 321 10.1111/j.1468-1293.2008.00560.x 18331562
27. Evaluation of a systematic substitution of zidovudine for stavudine-based HAART in a program setting in rural Cambodia. P Isaakidis ME Raguenaud T Phe SA Khim S Kuoch S Khem T Reid L Arnould, J Acquir Immune Defic Syndr 2008 49 1 48 54 10.1097/QAI.0b013e31817bec19 18667931
28. Changing characteristics of HIV-infected patients initiating antiretroviral therapy in East African from 2003-2008. PW Hunt K Wools-Kaloustian S Kimaiyo L Diero WM Tierney BS Musick P Braitstein MB Bwana E Geng DR Bangsberg JN Martin CT Yiannoutsos, 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention Cape Town 2009